Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

Launched by RARE THYROID THERAPEUTICS INTERNATIONAL AB · Oct 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of stopping a medication called tiratricol in boys with a condition known as Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency). The trial aims to find out if stopping tiratricol will cause an increase in a hormone called T3 in the body, which may lead to the need for rescue treatment. Boys aged 4 years and older who have been diagnosed with a specific genetic mutation related to this condition and have been stable on tiratricol treatment are eligible to participate.

During the study, participants will be randomly assigned to either continue receiving tiratricol or switch to a placebo (a dummy treatment) for 30 days. Researchers will closely monitor their hormone levels to see how stopping the medication affects them. It's important for families to know that participants should not have had major health issues recently and must not be taking other thyroid medications. The trial is currently recruiting participants, and informed consent from parents or legal guardians is required for enrollment.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Male participants diagnosed with a pathogenic mutation in the MCT8 gene, confirmed with a genetic test.
• 2. Serum total T3 concentration above the ULN of the age specific normal range:
• • 1. at the time of diagnosis (or the closest sample taken prior to first ever treatment with tiratricol) for participants who are currently treated with tiratricol
• • 2. in the Screening Visit sample, or most recent standard of care sample prior to screening, for participants who have never received and/or currently not receiving tiratricol.
• • 3. Participants will be aged 4 years or older at the time of randomization. Participants entering screening who are \<4 years of age but expected to be aged 4 years at randomization should be discussed with the medical monitor.
• • 4. Signed and dated informed consent form from the parents or legal guardian.
• Exclusion Criteria:
• 1. Major illness or recent major surgery unrelated to MCT8 deficiency (in the principal investigator's judgement), defined as:
• • Conditions requiring repeated hospitalizations that are likely to confound ability to participate in the trial.
• • Major illness in the 3 months prior to the screening visit that is likely to confound the ability of the participant to participate fully within the trial and/or confound the assessment of serum total T3 and/or safety.
• • Major surgery within the 3 months prior to the screening visit or planned to take place during the study, including but not limited to major abdominal/thoracic/neurosurgical procedures.
• • Major/minor abdominal and/or maxillofacial surgery that may inhibit the administration and/or absorption of study drug.
• • 2. Body weight \<10 kg at the Screening Visit.
• • 3. Patients who are participating, or intend to participate, in other therapeutic and/or interventional clinical studies during the study period.
• • 4. History of allergic reactions to components of tiratricol or any excipients in the investigational product (IP).
• • 5. Participants with any contra-indication for treatment with tiratricol or any excipients in the IP.
• • 6. Participants using other T3 analogues, levothyroxine, or propylthiouracil.
• Randomization Criteria:
• • In addition to the eligibility criteria, participants must meet further criteria at the time of randomization to enter the Randomized Treatment Period.
• • 1. Confirmation that the "Stable Dose Criterion" has been met.
• • 2. Absence of any new or exacerbated medical or surgical condition that fulfils Exclusion criterion #1.
• • 3. Confirmation that participant is at least 4 years of age at the time of randomization.